Back to search results

SIRPant-M for Relapsed or Refractory Non-Hodgkin's Lymphoma

This study is testing a new cell therapy called SIRPant-M, either by itself or with a type of radiation called external-beam radiotherapy (XRT), for people with non-Hodgkin's lymphoma (NHL) that has come back (relapsed) or hasn't responded to other treatments (refractory). SIRPant-M is made from your own immune cells and injected directly into your tumor. The main goal is to see if SIRPant-M, with or without radiation, is safe and well-tolerated. You could be eligible if you are an adult, have relapsed or refractory lymphoma, and have already tried at least two other treatments. This study plans to enroll 24 participants.

Study design
This is an open-label study, meaning you and your doctors will know which treatment you are receiving. It will enroll about 24 participants to test different doses of SIRPant-M alone or with radiation.
What's involved
You will receive SIRPant-M injections into your tumor, possibly with radiation to the injected area. The injections are given over several days, and some participants may receive a second cycle of treatment.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for about one year (364 days) after your treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05967416

Study of SIRPant-M in Participants With Relapsed or Refractory Non-Hodgkin's Lymphoma

Recruiting
PHASE1Ages 18+InterventionalTreatment
SIRPant Immunotherapeutics, Inc.
~24 participants
Updated 2024-12-20 on ClinicalTrials.gov
What's tested:SIRPant-MExternal-beam radiotherapy (XRT)

At a glance

Recruiting sites
3 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment emergent adverse events (TEAEs) and adverse events (AEs)
Measured over Day -42 through Day 364

Conditions

Refractory Non-Hodgkin Lymphoma
Relapsed Non-Hodgkin Lymphoma

Explore related trials

Adult T-Cell Leukemia/LymphomaAnaplastic Large Cell LymphomaChronic Lymphocytic LeukemiaDiffuse Large B-Cell LymphomaFollicular Helper T-Cell Lymphoma, Angioimmunoblastic-TypeFollicular LymphomaLymphomatoid PapulosisMantle Cell LymphomaMycosis FungoidesNodal Marginal Zone LymphomaNon-Hodgkin LymphomaPeripheral T-Cell Lymphoma, Not Otherwise SpecifiedPrimary cutaneous B-cell lymphomaPrimary Cutaneous T-Cell Non-Hodgkin LymphomaSezary SyndromeSmall Lymphocytic Lymphoma

Where it's being run

3 sites across 3 states
California1
New Jersey1
Texas1

Study leadership

  • Jelle Kijlstra, MD, MBA · STUDY_DIRECTOR · BobcatBio, p/k/a SIRPant Immunotherapeutics

Who to contact

Jelle Kijlstra, MD, MBA
[email protected]
206-909-1125
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

What this trial measures

  • Incidence of treatment emergent adverse events (TEAEs) and adverse events (AEs)Day -42 through Day 364

    Includes evaluation of frequency and severity of AEs, serious adverse events (SAEs), TEAEs, and adverse events of special interest (AESIs), including injection site reactions and abnormalities in clinical laboratory assessments, vital signs, or physical examination findings. Graded according to Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0.